AEON Biopharma, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 29, 2024. AEON is a clinical-stage biopharmaceutical company developing ABP-450, a botulinum toxin complex, for therapeutic indications. It has no approved therapeutic products and has generated no product revenue. The July 2023 merger created separate Predecessor and Successor reporting periods, so 2023 results are not directly comparable with 2022.
Financial and liquidity highlights
| Metric | Reported amount |
|---|---|
| Revenue | No product revenue in the periods presented. |
| Operating expenses | Predecessor, Jan. 1–July 21, 2023: $29.6 million; Successor, July 22–Dec. 31, 2023: a net operating credit of $29.6 million, including a $52.8 million contingent-consideration fair-value gain; 2022: $48.4 million. |
| Net result | Predecessor period: $60.7 million net loss; Successor period: $24.0 million net income; 2022: $52.6 million net loss. Successor-period income was substantially affected by noncash fair-value movements, not product sales. |
| Research and development | $19.8 million in the Predecessor period and $13.2 million in the Successor period; $34.8 million in 2022. The filing attributes the decrease primarily to winding down cervical dystonia Phase 2 activity. |
| Selling, general and administrative | $9.8 million in the Predecessor period and $9.9 million in the Successor period; $13.7 million in 2022. The filing cites merger-related legal and professional fees and stock-based compensation as drivers of the increase. |
| Cash and liquidity | Cash was $5.2 million at Dec. 31, 2023, versus $9.7 million at Dec. 31, 2022. Current assets were $6.2 million and current liabilities $13.0 million at year-end 2023. |
| Cash flows | Net cash used in operations: $21.7 million in the Predecessor period and $26.1 million in the Successor period, versus $35.6 million in 2022. Financing provided $14.0 million in the Predecessor period and none in the Successor period; investing cash flow was zero in both 2023 periods. |
| Debt and other liabilities | No convertible notes were outstanding on the Dec. 31, 2023 balance sheet; the Predecessor’s notes converted into shares at the merger. Successor total liabilities were $159.9 million, including a $104.4 million contingent-consideration liability and $41.0 million of embedded forward-purchase and derivative liabilities. Stockholders’ deficit was $153.0 million. |
| Margins | Not meaningful because the company reported no product revenue. |
The company reported an accumulated deficit of $473.6 million. Management concluded that substantial doubt exists about its ability to continue as a going concern because it cannot fund obligations for the year following issuance of the financial statements without additional financing. The auditor’s report also highlights the going-concern uncertainty.
Material changes and operating developments
- The July 21, 2023 merger and change in accounting presentation split results into Predecessor and Successor periods. As a result, there is no directly comparable, consolidated 2023 annual result in the filing.
- In October 2023, AEON reported that its Phase 2 episodic migraine trial did not meet its primary endpoint. It reported statistical significance on multiple secondary and exploratory endpoints and a favorable safety profile; these findings do not establish efficacy for approval.
- The Phase 2 cervical dystonia study met its primary endpoint and several secondary endpoints. Further development, including Phase 3, depends on securing capital.
- The chronic migraine Phase 2 cohort remained ongoing. At the filing date, AEON expected an interim topline update in Q2 2024 and full topline data in Q3 2024. Management also reported a successful FDA end-of-Phase-2 meeting in Q1 2024 supporting advancement to a pivotal migraine Phase 3 study.
- Gastroparesis had an accepted IND, but a Phase 2a study was subject to funding. AEON also had an ongoing preclinical study related to potential neuropsychiatric applications.
Outlook, risks, contingencies and unusual items
- Funding outlook: At the filing date, AEON expected cash to fund its operating plan through June 2024, including up to $15 million of Daewoong financing. A $5 million senior secured convertible note was issued on March 24, 2024; a further $10 million note was conditional on specified requirements. The notes bear 15.79% annual interest, mature three years after funding and are convertible subject to their terms. Management said additional capital would be required for further development.
- Development and commercial risks: ABP-450 is AEON’s only product candidate. Regulatory approval, trial outcomes, market adoption, reimbursement and commercialization are uncertain. The episodic migraine primary-endpoint miss is a material development risk; planned trials and program timelines depend on financing.
- Key third-party dependence: Daewoong is the sole manufacturer and supplies ABP-450 under an exclusive license and supply agreement. A March 2024 amendment allows termination under specified circumstances if AEON ceases both commercialization and clinical advancement in covered territories for six months. In certain termination circumstances, Daewoong may acquire related know-how for $1.
- Forward-purchase termination: In March 2024, ACM and Polar terminated their forward purchase agreements and retained 3.1 million and 3.175 million shares, respectively, as well as the associated prepayment amounts; AEON received no cash for those retained shares. AEON may owe up to $3.0 million in registration-related liquidated damages. The filing says it expects to record an approximately $20.3 million charge in Q1 2024 to reverse related balances.
- Accounting and controls: A $52.8 million noncash gain from remeasurement of contingent consideration materially affected Successor-period operating results. AEON reported material weaknesses in internal control over financial reporting, including weaknesses involving complex transaction accounting and valuation inputs; disclosure controls were not effective at year-end. The filing says the weaknesses resulted in a restatement of previously reported quarterly financial statements. Management’s remediation efforts were ongoing.
- Legal matter: Odeon Capital Group sued in September 2023, claiming a $1.25 million deferred underwriting fee and seeking additional damages and fees. AEON moved to dismiss certain claims; the filing does not state an outcome or a clear estimate of potential total exposure.
- Potential dilution: The company disclosed warrants, convertible-note conversion rights, equity awards and up to 16 million milestone-based contingent shares. The potential share impact depends on exercise, conversion and milestone outcomes.
Important facts for investors to verify
- Confirm the timing, terms and funding status of the remaining Daewoong financing, and the company’s actual cash runway and financing needs.
- Review final chronic migraine data and the FDA-agreed Phase 3 design, while assessing the implications of the episodic trial’s missed primary endpoint.
- Track remediation and independent validation of the reported internal-control weaknesses and any further corrections to previously reported results.
- Verify the accounting and cash consequences of the terminated forward purchase agreements, including any liquidated damages and the expected Q1 2024 charge.
- Assess the Daewoong agreement’s termination provisions and manufacturing concentration, as well as the status and potential exposure of the Odeon lawsuit.
- Evaluate dilution from the convertible notes, warrants, equity awards and milestone-based share consideration against the shares outstanding.